Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Fludarabine
Related studies linked through entity extraction aliases.
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE1
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
- Status
- COMPLETED
- Phase
- PHASE2
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
- Status
- COMPLETED
- Phase
- PHASE2
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)
- Status
- UNKNOWN
- Phase
- NA
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
- Status
- COMPLETED
- Phase
- PHASE2
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE1
TIL Therapy for Metastatic Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma
- Status
- COMPLETED
- Phase
- PHASE1
HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk
- Status
- COMPLETED
- Phase
- PHASE3
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1